A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency
NCT02488044
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Arginase I Deficiency
Hyperargininemia
Interventions
DRUG:
AEB1102
Sponsor
Aeglea Biotherapeutics